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osting by EAbstract Purpose: To report the prevalence of anticardiolipin antibodies in patients with prolif-
erative diabetic retinopathy (PDR) having high-risk criteria (HRC).
Methods: Diabetic patients having PDR with HRC and diabetics free of retinopathy were com-
pared for the presence of anticardiolipin antibodies.
Results: Among the 34 patients, 6 (17.7%) of diabetics having PDR with HRC were positive for
anticardiolipin antibodies. There was no signiﬁcant association of aCL antibodies with sex or type
of diabetes. Using Pearson’s correlation test, no signiﬁcant associations of aCL antibodies with
duration of diabetes or age of patients were found. All patients who were positive for anticardio-
lipin antibodies had PDR with HRC. The difference was statistically signiﬁcant.
Conclusion: Presence of anticardiolipin antibodies may represent an additional risk factor for
PDR.
ª 2009 King Saud University. All rights reserved.1. Introduction
Diabetic retinopathy (DR) is a major cause of blindness in the
working population of the Western world; the prevalence of216440; fax: +20 50 2256104.
(M. Shahin).
ity. All rights reserved. Peer-
d University.
lsevierwhich is strongly related to the duration of diabetes and the
glycemic control (Leske et al., 2006). Intensive diabetic man-
agement, with the goal of achieving near-normal glycemic con-
trol may prevent and/or delay the onset of DR. There is now
ample evidence that the development of microangiopathy is
a multifactorial process in which genetic, metabolic and
growth factors may play an important role (Geiusti, 2004).
Leske et al. (2006) have suggested a possible low risk of severe
proliferative diabetic retinopathy (PDR) among persons of
African origin than in whites. In addition, intravitreal vascular
endothelial growth factor (VEGF) but not hepatocytes growth
factor (HGF) has been found to be related to PDR activity
(Simo et al., 2006).
Antiphospholipid antibodies (aPA) are autoantibodies that
target one or more phospholipids (PL) or PL-binding proteins
166 M. Shahin et al.present on cellular membranes (McIntyre et al., 1997). They
have been described in patients having lupus erythematosus
(Vogel et al., 1991), recurrent abortion (Peluso and Morrone,
2007), ocular ischemia (Hughes, 1993), ischemic heart disease
(Foley Nalan et al., 1991), atherosclerosis, stroke and transient
ischemic attack (Toschi et al., 1998), solid organ grafts (McIn-
tyre and Wagenknecht, 2001), and diabetes (Geiusti, 2004).
Antiphospholipid antibodies, including anticardiolipin
antibodies (aCL), are detected in many conditions, but only
those found in association with autoimmune disease require
the presence of phospholipid binding serum protein beta-2 gly-
coprotein I (B2GPI) (Iverson et al., 2004). B2GPI is composed
of ﬁve homologous domains numbered I–V from the N-termi-
nus. Domains I–V are designated short consensus repeats
(complement control protein repeats or ‘‘sushi domains’’)
and are composed of approximately 60 amino acids that con-
tain a motif characterized by four conserved cysteine residues
which form two internal disulﬁde bridges (Kato and Enjoji,
1991). The modiﬁed ﬁfth domain differs from domains I–IV
in that it contains 82 amino acids resulting in a C-terminal
loop with an additional disulﬁde bond (Hunt et al., 1993).
Understanding anticardiolipin autoantibodies has been the fo-
cus of signiﬁcant interest due to their accepted role in the
pathology of antiphospholipid syndrome (APS). Antiphospho-
lipid syndrome is an autoimmune disorder associated with
arterial and venous thromboses and recurrent fetal loss (Derk-
sen and de Groot, 2004). Anticardiolipin antibodies are not di-
rected against cardiolipin, but rather the complex of
cardiolipin and the plasma protein cofactor beta-2 glycopro-
tein I (B2GPI). At present, B2GPI is considered the true anti-
genic target for aCL antibodies (Passam and Krilis, 2004). The
presence of immunological markers in the blood vessel walls
has been documented for some time (Burkholder, 1965). The
presence of autoantibodies to endothelial cell surface antigens
may initiate vascular injury (Bordron et al., 1998). Recent evi-
dence suggests that DR may be due to an autoimmune process
(Kastelan et al., 2007).
Antiphospholipids antibodies, including anticardiolipin
(aCL) antibodies, are autoantibodies that target one or more
phospholipids (PL) or PL-binding proteins present on cellular
membranes (McIntyre et al., 1997), which may be associated
with arterial and/or venous thrombosis (Hughes, 1993). Immu-
nological mechanisms may play a role in the pathogenesis of
diabetic microangiopathy via immune complex deposition.
Antiphospholipid antibodies directed against endothelial anti-
gens may be responsible for initiating vascular injury, these
could be a marker of endothelial dysfunction (Geiusti, 2004).
There is a recognized association between aCL antibodies pres-
ence and vascular occlusive disease (Kalogeropoulos et al.,
1998).
The purpose of this study was to determine the prevalence
of anticardiolipin antibodies in patients with proliferative dia-
betic retinopathy (PDR) with high-risk criteria (HRC) and to
investigate whether aCL antibodies presence may be relevant
to the pathogenesis DR.
2. Patients and methods
The study was approved by the human ethics committee and
all patients signed informed consent before entering the study.
All applicable institutional and governmental regulationsconcerning the ethical use of human volunteers were followed
during this research.
Two hundred consecutive diabetic patients attending
Mansoura Ophthalmology Center from November, 2006 to
February, 2007 were screened for signs of PDR with HRC. Pa-
tients were classiﬁed according to the National Diabetes Data
Group (National Diabetes Data Group, 1979). Retinal vascu-
lar morphology was evaluated by colour fundus photography.
High-risk criteria were deﬁned according to the Diabetic Ret-
inopathy Study Research Group criteria (Diabetic Retinopa-
thy Study Research Group, 1981). Exclusion criteria were
poor glycemic control (HbA1c > 9%), borderline hyperten-
sion (>140/90), hypertriglyceridaemia (>1.9 mmol/L), or
hypercholesterolaemia (>5.6 mmol/L), smoking and hazy
media.
Thirty-four diabetics were enrolled in the study. Thirty-six
comparable diabetic patients free of diabetic retinopathy were
selected as control group. The groups were comparable with
regard to age, sex and duration of disease. All 70 patients
underwent ophthalmologic examination including visual acu-
ity, slit lamp examination, fundus contact lens examination
and ﬂuorescein angiography. Five milliliters of venous blood
was withdrawn from each patient. The samples were centri-
fuged and separated sera were stored in deep freezer at
70 C until the time of assay. Serum samples were examined
for anticardiolipin antibodies. IgG and IgM were determined
using Enzyme-Linked Immuno-Sorbent Assay (ELISA)
technique.
Anticardiolipin antibodies (IgG and IgM) were determined
by using ELISA. Patients were considered positive for IgG
aCL antibodies when it was >10 GPL unit/ml and negative
when the titer <10 GPL unit/ml. Patients were considered po-
sitive for IgM aCL antibodies when it was >7 MPL unit/ml
and negative when the titer was <7 MPL units/ml. For
descriptive statistics of the quantitative variables, the mean,
range and standard deviation were used to describe central ten-
dency and dispersion. Differences between the means of the
independent samples were analyzed by the Student’s t tests.
Pearson’s correlation and Fisher’s exact probability tests were
used to compare study and control groups and to test associa-
tion between aCL and other factors such as age, sex, duration
of the disease, type of diabetes, and presence of PDR with
HRC. All tests were considered signiﬁcant if (P< 0.05).
3. Results
The study included 70 diabetic patients (33 males, 37 females,
age range 22–68 years). Thirty patients were type 1 diabetics
while 40 patients were type 2 diabetics. Thirty-four patients
had PDR with HRC while 36 were free from diabetic retinop-
athy. Both groups showed no statistical difference regarding
age of patients, duration of diabetes, sex or type of diabetes
(Table 1).
Table 2 summarizes aCL positivity. Six patients were posi-
tive for aCL antibodies. Fisher’s exact probability test showed
no signiﬁcant associations of aCL antibodies with sex or type
of diabetes. Using Pearson’s correlation test, no signiﬁcant
associations of aCL antibodies with duration of diabetes or
age of patients were found. Six of 70 diabetic patients
(8.6%) were positive for aCL antibodies. All of them had
IgG antibodies while two (2.9%) had IgM antibodies. 17.7%
Table 1 Characteristics of patients having PDR with HRC and control diabetics free of diabetic retinopathy.
Diabetic patients free of diabetic retinopathy PDR patients with HRC P value
Age (years) 44.9 ± 15.1 46.5 ± 13.8a 0.3
Sex (M/F) 15(42)/21(58) 18(53)/16(47)b 0.4
Duration (years)
Mean ± SD 13.1 ± 2.7 14 ± 3.1 0.4
Median 14 13
Range 8–20 9–18
Type of diabetes (1/2) 12(33%)/24(67%) 18(53%)/16(47%) 0.1
Total number (%) 36(51.4%) 34(48.6%)
a Mean ± SD.
b Number of patients (percentage of total).








having PDR with HRC
IgG 0 (0%)a 5 (27.8%) 0 (0%) 1 (6.3%)
IgM 0 (0%) 2 (11.1%) 0 (0%) 0 (0%)
Total number 12 18 24 16
a Number of patients (percentage of total).
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patients with aCL positivity had PDR with HRC. Most fre-
quent isotype IgG was more common in type 1 than type 2.
Five patients were type 1 diabetics (two of them had both
IgG and IgM antibodies and three had IgG only) while one pa-
tient was type 2 diabetic (IgG antibodies). None of diabetic
retinopathy-free patients was positive for aCL antibodies.
The presence of aCL was detected in 6 (17.7%) patients
(three males and three females) having PDR with HRC. Fish-
er’s exact probability test was statistically signiﬁcant
(P= 0.01). In type 1 diabetics, aCL was found in 27.8% of
PDR patients with HRC. On the other hand, aCL was found
in only 6.3% of type 2 diabetics having PDR with HRC (Table
3).4. Discussion
The vascular endothelium is a major regulator of haemostasis.
Vascular damage and endothelial cell dysfunction occur early
in the course of diabetic microangiopathy (Barnett, 1991).
The net effect of these changes is the conversion of endothe-
lium from a thromboresistant to a thrombogenic surface (Gar-
giulo et al., 1997). Autoantibodies to endothelial cell surface
antigens initiate vascular injury (Bordron et al., 1998). TheTable 3 The frequency of aCL antibodies in the studied patients.
No retinopathy
Type 1 0/12 (0%)
Type 2 0/24 (0%)
Total 0/36 (0%)
a Fisher’s exact test.molecular mechanism by which aCL antibodies activate vascu-
lar endothelial cells is not known. Numerous studies suggest
that exogenous B2GPI, a circulating glycoprotein, is necessary,
and aCL recognize a complex antigen that includes B2GPI and
anionic phospholipids (McNeil et al., 1990). It is likely that the
interaction of circulating B2GPI with endothelial cell anionic
phospholipid induces formation of a neoepitope that confers
recognition speciﬁcity for aCL. Association between the pres-
ence of the IgG isotype and thrombosis in patients with APS
has been demonstrated previously (Cabiedes et al., 1995).
Although B2GPI has been shown to be necessary for the
anticardiolipin-mediated pathophysiological effect, a sugges-
tion that an endothelial cell membrane protein acts as a cofac-
tor cannot be excluded (Simantov et al., 1995). However, there
has been no reliable predictor of thrombotic events in patients
with aCL antibodies. Anticardiolipin antibodies are found in
the immunoglobulin classes IgG, IgM and/or IgA. The deter-
mination of IgA antibodies seems to have a greater importance
in the African-Caribbean population (Molina et al., 1997). In
the present study IgG and IgM were studied. Horbach et al.
(1996) demonstrated the relationship between IgM, aCL anti-
bodies and venous thrombosis. Other study found a signiﬁcant
association between IgG isotype and thrombosis, especially
arterial but not venous (Ogawa et al., 2000). In addition,




168 M. Shahin et al.ders. The most represented feature of posterior involvement in
patient with abnormal aCL antibodies was retinal vasculitis
(60%) (Miserocchi et al., 2002). A statistically signiﬁcant prev-
alence of aCL antibodies has been found in patients with ret-
inal vascular occlusive disorders in the absence of main
accepted risk factors for retinal thrombosis (Cobo-Soriano
et al., 2000). A simultaneous bilateral central retinal vein
occlusion was found to be associated with anticardiolipin anti-
bodies in a leukamic patient (Al-Abdulla et al., 2001). The inci-
dence of aCL IgG was higher in patients with Behcet’s disease
with non-occlusive thrombosis than in patients with retinal
occlusive events or in patients without occlusions or thrombo-
sis (Ermakova et al., 2002).
Although aCL antibodies have been associated with a large
number of diseases, there are only a few studies of these anti-
bodies in DR patients. In the present study aCL antibodies
were examined in patients having PDR with high-risk criteria.
Both type 1 and type 2 diabetics were studied because they dif-
fer in their auto antibodies (Wroblewski et al., 1998) and in
their immunogenetics (Schranz and Lemmark, 1998) and they
do not share genetic susceptibility loci (Elbein et al., 1997). In
their study, Gargiulo et al. (1999) found that the prevalence of
IgG aCL antibodies in diabetic population (type 1 and type 2)
was found to be 8.9% while the prevalence of IgM aCL was
found to be 5.9%. In their normal population, the prevalence
of IgG aCL was found to range from 4% to 4.9% (Ahmed
et al., 1999; Merkel et al., 1996; Diez et al., 1993) and the prev-
alence of IgM aCL was found to be 2.8% (Diez et al., 1993).
The levels of IgM aCL antibodies has been found to be
more prevalent in type 1 diabetics with vascular complications
than in type 1 diabetics without complications (Ahmed et al.,
1999). The incidence of antiphospholipid antibodies has been
found to be equally high in type 1 and type 2 diabetics with ret-
inopathy (Simo et al., 2006). The autoantibodies to endothelial
cell surface antigens that initiate vascular injury (Bordron
et al., 1998; Jones et al., 1992), can be associated with arterial
and/or venous thrombosis (Hughes, 1993). The most plausible
explanation for endothelial proliferation and neovessels for-
mation in the retina is ischemia of its inner layers secondary
to closure of parts of retinal capillary bed (Michelson, 1948;
Wise, 1956). The ischemic retina produces a new vessel-stimu-
lating factor, capable of acting locally and diffusing through
the vitreous to other areas of the retina, to the optic disc,
and into the anterior chamber (Wise, 1956; Patz, 1982). The
possibility that these antibodies may be secondary to neoves-
sels formation should be considered in further studies.
An immunological basis for diabetic microangiopathy has
been suggested by studies showing an increased deposition of
immunoglobulins and antigen–antibody complexes in the
basement membrane of small blood vessels (Bloodworth,
1968). Mimura et al. found that the production or existence
of glutamic acid decarboxylase autoantibodies may contribute
to the prevention of retinopathy (Mimura et al., 2004). Dia-
betic retinopathy has been suggested to be an autoimmune dis-
ease based on the ﬁnding of antipericyte and antiendothelial
cell autoantibodies in the circulation of diabetic patients. More
evidence implicates the presence of autoimmune mechanisms
in the proliferative stage of this disease: elevated levels of tu-
mor necrosis factor-alpha, interleukin-8 and soluble interleu-
kin-2 receptor in the serum of diabetic patients, increased
vitreous concentration of the interleukin-6 and interleukin-8
in patients with PDR (Kastelan et al., 2007).In the present study, there is signiﬁcant increase in the aCL
in patients having PDR with HRC suggesting that aCL could
represent an additional risk factor for proliferative diabetic ret-
inopathy. The pathological shift of vascular endothelium from
antithrombotic to a prothrombotic state may be more pro-
nounced in subjects with anticardiolipin positivity and/or high
circulating immune complexes concentrations since they pos-
sess the ability not only to induce platelet activation and aggre-
gation but also to activate the complement system via the
classical pathway. Therefore, a potential synergism between
generation of antibodies, haemostatic alterations and endothe-
lial stress has been suggested (Geiusti, 2004).
Further immunochemical investigations are needed to clar-
ify whether this autoimmune reaction is the cause, conse-
quence or aggravating factor of the disease. With the
understanding of new cellular and molecular mechanism, a
new generation of therapeutic strategies may be envisioned.
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